A Study of Safety Tolerability and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma

A
Anita Turk

Primary Investigator

Overview

The purpose of this study is to see if two investigational drugs, called MEDI4736 and tremelimumab (either drug alone or in combination) are safe in treating adult subjects with liver cancer (hepatocellular carcinoma) that cannot be removed by surgery (unresectable).

Description

The purpose of this study is to see if two investigational drugs, called MEDI4736 and tremelimumab are safe in treating adult subjects with liver cancer that cannot be removed by surgery.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    liver cancer,hepatocellular carcinoma
  • Age: Between 18 Years - 100 Years
  • Gender: All

Inclusion Criteria
In order to be eligible to take part in this trial, patients must meet the following criteria:

  • 18 years or older
  • Confirmed diagnosis of unresectable hepatocellular carcinoma with or without concomitant viral hepatits B or hepatitis C infection

For a full list of participation criteria, please visit clinicaltrials.gov.


Additional Information:
Participants will be compensated for their participation.

Updated on 20 Nov 2022. Study ID: 1601354641

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center